PIK3CD and cancer: In support of this, a study of a number of PI3K inhibitors from different chemotypes in a panel of 39 cancer cell lines in vitro and 24 in vivo tumourxenografts found a significant association of activating RAS or BRAF mutations with resistance to inhibition of the PI3K pathway [130].